Assessment Questions: SGLT2 Inhibitors in the ICU – Pharmacy & Acute Care University

Skip to content

ACPE Accredited** Pharm So Hard Emergency Medicine Podcast Episodes SGLT2 Inhibitors in the ICU – Are We Missing an Opportunity? Assessment Questions: SGLT2 Inhibitors in the ICU

Time limit: 0

Quiz Summary

0 of 10 Questions completed

Questions:

Information

You have already completed the quiz before. Hence you can not start it again.

Quiz is loading…

You must sign in or sign up to start the quiz.

You must first complete the following:

Results

Quiz complete. Results are being recorded.

Results

0 of 10 Questions answered correctly

Your time:

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

1
2
3
4
5
6
7
8
9
10

Current
Review
Answered
Correct
Incorrect

Question 1 of 10

1. Question
What is the primary function of SGLT2 inhibitors in the body?
- Blocking glucose absorption in the intestines
- Increasing insulin production in the pancreas
- Preventing glucose reabsorption in the kidneys
- Enhancing glucose uptake in muscle cells
Correct

Incorrect
Question 2 of 10

2. Question
Why did the FDA mandate cardiovascular outcome testing for anti-diabetic drugs in 2008?
- To find new uses for diabetes medications
- Due to safety concerns from previous drugs like rosiglitazone
- To ensure all drugs lower blood sugar effectively
- To compare them with insulin-based treatments
Correct

Incorrect
Question 3 of 10

3. Question
What class of drugs is the focus of this podcast episode?
- Beta-blockers
- SGLT2 Inhibitors
- Statins
- ACE Inhibitors
Correct

Incorrect
Question 4 of 10

4. Question
What was the initial purpose of SGLT2 inhibitors?
- Anti-hypertensive treatment
- Diabetes management
- Pain relief
- Anti-inflammatory medication
Correct

Incorrect
Question 5 of 10

5. Question
What unexpected benefit was discovered in SGLT2 inhibitors during cardiovascular outcome testing?
- No effect on cardiovascular health
- Harmful effects on kidney function
- Cardiovascular and renal benefits
- Increased blood sugar levels
Correct

Incorrect
Question 6 of 10

6. Question
What was the name of the trial discussed in depth during the episode?
- EMPA-REG
- DAPA-HF
- DEFENDER
- IMPACT
Correct

Incorrect
Question 7 of 10

7. Question
What was the primary outcome measured in the DEFENDER trial?
- Reduction in ICU admissions
- Composite of hospital mortality, need for dialysis, and ICU length of stay
- Increased glucose reabsorption
- Reduction in blood sugar levels
Correct

Incorrect
Question 8 of 10

8. Question
What was the key finding of the DEFENDER trial regarding ICU patients?
- Significant reduction in ICU length of stay
- No statistical significance in mortality benefit
- Increased risk of hypoglycemia
- SGLT2 inhibitors were unsafe for ICU patients
Correct

Incorrect
Question 9 of 10

9. Question
What safety concerns about SGLT2 inhibitors were addressed in the episode?
- Increased bleeding risk
- Increased risk of hypoglycemia, DKA, and infections
- Severe allergic reactions
- High blood pressure
Correct

Incorrect
Question 10 of 10

10. Question
Why did the host suggest another study should be conducted?
- To further explore renal benefits in critically ill patients
- To test SGLT2 inhibitors on a different population
- To compare SGLT2 inhibitors with statins
- To test the effectiveness of different insulin regimens
Correct

Incorrect

Pharmacy & Acute Care University, Proudly powered by WordPress. Privacy Policy

Login

Accessing this course requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?

Register

Don't have an account? Register one!

Register an Account

Username

Email

Registration confirmation will be emailed to you.